Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

05 Feb 2022

Acupuncture seems to be better than pharmacotherapy at relieving emotional symptoms in patients with functional gastrointestinal disorders (FGIDs), reports a recent meta-analysis.

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

05 Feb 2022

Immunomodulator withdrawal not linked to loss of response in IBD

02 Feb 2022

Among inflammatory bowel disease (IBD) patients, the discontinuation of immunomodulator treatment does not contribute to the risk of loss of response although it may lead to an increase in antidrug antibodies, according to a study.

Immunomodulator withdrawal not linked to loss of response in IBD

02 Feb 2022

Plecanatide may be safely administered with antacid

31 Jan 2022 bởi

Acid suppression therapy appears to exert no meaningful effect on the efficacy or safety of plecanatide when administered concomitantly, according to a study.

Plecanatide may be safely administered with antacid

31 Jan 2022

Postop adjuvant treatment yields survival benefit for stage IIB-III oesophageal SCC

31 Jan 2022 bởi

The addition of postoperative radiotherapy (PORT) or postoperative concurrent chemoradiotherapy (POCRT) to surgery led to significant improvements in disease-free survival (DFS) and overall survival (OS) in individuals with pathological stage IIB-III oesophageal squamous cell carcinoma (SCC) compared with surgery alone, a prospective phase III study from China suggests.

Postop adjuvant treatment yields survival benefit for stage IIB-III oesophageal SCC

31 Jan 2022

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022 bởi

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022

Pregnant women with type 1 diabetes likely to have gut inflammation

29 Jan 2022

Women with type 1 diabetes present with a shift in the gut mycobiome across pregnancy, and this shift is strongly linked to gut inflammation and impaired intestinal barrier function, as reported in a study.

Pregnant women with type 1 diabetes likely to have gut inflammation

29 Jan 2022

Could bariatric surgery prevent severe COVID-19?

28 Jan 2022 bởi

Individuals who have undergone bariatric surgery to treat obesity may have a reduced risk of developing severe COVID-19, according to a recent study.

Could bariatric surgery prevent severe COVID-19?

28 Jan 2022

Low FODMAP diet promising in management of persistent symptoms in coeliac disease

27 Jan 2022

For treated patients with coeliac disease (CD) who are experiencing persistent symptoms, a short-term diet with moderately low fermentable oligo-, di-, monosaccharides and polyols (FODMAP) helps reduce gastrointestinal symptoms and improve CD-specific health, as suggested in a study.

Low FODMAP diet promising in management of persistent symptoms in coeliac disease

27 Jan 2022

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

26 Jan 2022 bởi

Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

26 Jan 2022

Investigative drug for ulcerative colitis passes muster in early trial

25 Jan 2022

The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.

Investigative drug for ulcerative colitis passes muster in early trial

25 Jan 2022

Tin tức & Cập nhật

Xem bài viết Tiêu hóa

Xem

Chuyên ngành:

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

Acupuncture bests pharmacotherapy for relieving depression, anxiety in FGID patients

Immunomodulator withdrawal not linked to loss of response in IBD

Immunomodulator withdrawal not linked to loss of response in IBD

Plecanatide may be safely administered with antacid

Plecanatide may be safely administered with antacid

Postop adjuvant treatment yields survival benefit for stage IIB-III oesophageal SCC

Postop adjuvant treatment yields survival benefit for stage IIB-III oesophageal SCC

Real-world data reflect promising efficacy, safety of ozanimod for UC

Real-world data reflect promising efficacy, safety of ozanimod for UC

Pregnant women with type 1 diabetes likely to have gut inflammation

Pregnant women with type 1 diabetes likely to have gut inflammation

Could bariatric surgery prevent severe COVID-19?

Could bariatric surgery prevent severe COVID-19?

Low FODMAP diet promising in management of persistent symptoms in coeliac disease

Low FODMAP diet promising in management of persistent symptoms in coeliac disease

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

Investigative drug for ulcerative colitis passes muster in early trial

Investigative drug for ulcerative colitis passes muster in early trial